browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
eea6ae42-9e0a-41b9-b093-0975cae9c527
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 15:19:40
Income (reported)
Expenses (reported)
$2,550,000
Expenses method
A
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

HUMANA, INC.

Contact
MICHELLE ESPINAL
Phone
+1 407-922-7166
Address
zip:40202, city:LOUISVILLE, state:KY, street:101 E Main Street
Client

HUMANA INC

State
KY
Country
US
Government-entity client
false
Effective date
2007-08-14
Issues lobbied + lobbyists (4)

MMM — Medicare/Medicaid

Medicare Advantage (MA) Policy and Reimbursement Medicare Part D Issues Medicaid Policy Issues Including Dual Eligibles Pharmacy Benefit Managers (PBM) and Pharmacy Policy and Reimbursement Issues Home Health Policy and Reimbursement Issues Implementation of Inflation Reduction Act of 2022 Public Law No. 117-169 H.R. 3514/S.1816, Improving Seniors' Timely Access to Care Act of 2025 (119th Congress) Prior Authorization Policy and Regulatory Issues CMS-4185-F2 Medicare Advantage Risk Adjustment Data Validation Final Rule Primary Care and Value-Based Care Policy and Reimbursement Clinical Policy Issues Including Workforce and Mental Health Hospital Outpatient Prospective Payment System (OPPS): Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-2022 Final Rule (CMS 1793-F) Implementation of CMS Interoperability and Prior Authorization final rule (CMS-0057-F) Calendar Year (CY) 2025 Home Health Prospective Payment System Final Rule (CMS-1803-F) Contract Year 2025 Medicare Advantage and Part D Final Rule (CMS-4205-F) Announcement of Calendar Year (CY) 2025 Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies Final Calendar Year (CY) 2025 Part D Redesign Program Instructions Fiscal Year (FY) 2025 Hospice Payment Rate Update Final Rule (CMS-1810-F) PL 119-21, One Big Beautiful Bill Act S.1105, No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act H.R. 3467, Medicare Advantage Reform Act Policy issues related to VA-eligible Medicare beneficiaries Final Calendar Year (CY) 2026 Part D Redesign Program Instructions Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-F) Fiscal Year (FY) 2026 Skilled Nursing Facility (SNF) Prospective Payment System Final Rule (CMS-1827-F) Final Guidance for Medicare Drug Price Negotiation Program guidance for initial price applicability year 2028 CMS Health Tech Ecosystem initiative H.R. 1732, GUARD VA Benefits Act H.R. 5454/S. 2789, Medicare Advantage Prompt Pay Act Calendar Year (CY) 2026 Home Health Prospective Payment System Final Rule (CMS-1828-F) Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (CMS-4212-P) Calendar Year (CY) 2027 Advance Notice of Methodological Changes for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (the CY 2027 Advance Notice)

Lobbyists:

Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; White House Office

DEF — Defense

TRICARE Policy Issues including Telehealth, Value-Based Care, and T-5 Transition NDAA Implementation Policy Issues Veterans Healthcare and Policy Issues PL 118-159, Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025

Lobbyists:

Government entities lobbied: Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; SENATE; Veterans Affairs, Dept of (VA)

TAX — Taxation/Internal Revenue Code

Tax Reform Implementation Issues PL 119-21, One Big Beautiful Bill Act

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE; Treasury, Dept of; White House Office

PHA — Pharmacy

Prescription drug pricing Pharmacy Benefit Managers (PBM) and Pharmacy Policy and Reimbursement Issues

Lobbyists:

Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; White House Office

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.